Guide decisions during drug development with the information to make risk-reducing decisions earlier.

In biotherapeutic development, optimizing cell culture conditions is necessary to enable simpler, faster and more cost-effective drug delivery to patients. However, these changes can induce cellular stress and adversely impact product quality, creating additional challenges in manufacturing.

Reliable and streamlined workflows to characterize PTMs are necessary to create a comprehensive molecular profile. Workflows that provide these critical pieces of information with minimal processing allow for less labor-intensive characterization of PTMs.

Join the discussion on a single injection EAD-based middle-down characterization approach and discover:

• How middle-down fragment analysis can improve cell line optimization
• The use of middle-down analysis for structural confirmation of engineered disulfides
• The benefits of subunit workflows for cell line screening

Presented by:

Hirsh Nanda, PhD

Director, Analytical Sciences
J&J Innovative Medicine